Despite significant investment and a fourfold increase in use, traditional CGM systems are not moving the A1C needle. A recent report from the T1D Exchange shows only 21.5% of Type 1 adults are meeting the ADA A1C goal of 7.0%, and glycemic control has not improved overall since their report of data from 2010-2012.
Offer a unique implantable alternative to traditional CGM that overcomes common barriers hindering better patient control.
Diagnosed 10 years ago with Type 1 diabetes, 65-year old “Gerry” is an avid runner and former Medtronic CGM user. She disliked the sensor self-insertion process, and didn’t trust the accuracy of her readings, especially in the hypoglycemic range. As a result, she developed a fear of hypoglycemia, and found herself consuming extra carbs and limiting her distance to avoid unexpected swings. Eventually she abandoned CGM therapy, and her A1C rose to 8.1%. Gerry started using the Eversense CGM System in October 2018. She quickly came to trust her data, and the on-body vibe alerts helped her overcome her fears. She was able to run without worrying about her glucose, and felt this was one CGM that fit into her daily routine. After 5 months using Eversense, Gerry’s A1C dropped to 6.9%.
Eversense CGM user since October 2018 > 150 mg/dL average glucose > 0.3% time in severe hypoglycemic range (< 54 mg/dL) > 72% time in range (70-180 mg/dL) > 6.9% A1C after 5 months of useDownload Now
1 Foster NC, Beck RW, Miller KM, Rickels MR, et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018. Diabetes Technology & Therapeutics. Volume 21, Number 2, 2019.
2 Lind M, Polonsky, W, Hirsch, I, et al. The GOLD Randomized Clinical Trial. JAMA. 2017;317(4):379-387.
3 Battelino T, Liabat S, et al. Diabet Med. 2015;32(12):1568-74.
The photograph is for illustrative purposes only and depicts a stock photography model. The information presented is Gerry’s actual data shared with the permission of her and her physician.
The Eversense® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. It is intended to complement, not replace, fingerstick blood glucose monitoring. The sensor insertion and removal is performed by a health care provider. The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see https://eversensediabetes.com/safety-info/
MKT-001250 Rev 1 April 2019